Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Chief Financial Officer | March 10, 2022 | March 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date March 10, 2022 · Filed March 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2032-03-10 | Direct | 650,000 |
Reported balance
After 2022-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-10 · Grant · Acquired 650,000 · Balance 650,000 F1: One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. |
Filing footnotes · ownership attribution and instrument terms
F1: One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2022 Filed Mar 12, 2022 01:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001493152-22-006694 · ownership.xml · derivative · entry 1 Cook Kevin Leon · CIK 0001870539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Shares · 650,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:40 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantRestricted Stock Units · Derivative | 13,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-004716 · ownership.xml · derivative · entry 1 Cook Kevin Leon · CIK 0001870539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,888 Underlying: Common Shares · 13,888 shares Expires not disclosed F1 · derivative.exercise_price: Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share. F2 · derivative.exercise_date: Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023. F2 · derivative.expiration_date: Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023. Read SEC document |
| June 21, 2021 Filed Jul 1, 2021 20:21 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001493152-21-015851 · ownership.xml · derivative · entry 1 Cook Kevin Leon · CIK 0001870539 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Shares · 750,000 shares Expires 2031-06-20 F1 · derivative.exercise_date: This option will vest as to one quarter of the shares subject to the option on June 21, 2022, and the balance will vest in 36 successive substantially equal monthly installments thereafter, subject to the reporting person's continuous employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.